Merck KGaA (MRK) Earns Buy Rating from DZ Bank

Merck KGaA (FRA:MRK)‘s stock had its “buy” rating restated by DZ Bank in a research report issued to clients and investors on Wednesday, Borsen Zeitung reports.

Several other research analysts also recently issued reports on the company. Deutsche Bank set a €97.00 ($112.79) price objective on Merck KGaA and gave the stock a “neutral” rating in a research report on Thursday, May 9th. Nord/LB set a €80.00 ($93.02) price objective on Merck KGaA and gave the stock a “sell” rating in a research report on Thursday, January 24th. HSBC set a €96.00 ($111.63) price objective on Merck KGaA and gave the stock a “neutral” rating in a research report on Monday, March 11th. Sanford C. Bernstein set a €105.00 ($122.09) price objective on Merck KGaA and gave the stock a “buy” rating in a research report on Thursday, March 7th. Finally, Goldman Sachs Group set a €95.00 ($110.47) price objective on Merck KGaA and gave the stock a “neutral” rating in a research report on Tuesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of €101.25 ($117.73).

Shares of FRA:MRK traded down €0.54 ($0.63) during trading on Wednesday, hitting €90.30 ($105.00). 336,308 shares of the stock were exchanged. Merck KGaA has a 12-month low of €76.60 ($89.07) and a 12-month high of €115.00 ($133.72).

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Recommended Story: What is channel trading?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.